Pathophysiology and Treatment of Recessive RYR1 Related Myopathy

隐性 RYR1 相关肌病的病理生理学和治疗

基本信息

  • 批准号:
    10640863
  • 负责人:
  • 金额:
    $ 40.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-29 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

Mutations in the gene that encodes the skeletal muscle type I ryanodine receptor (RYR1) result in a wide range of muscle disorders that collectively comprise the most common cause of non-dystrophic myopathy. The most severe cases of RYR1-related myopathy (RYR1-RM) exhibit a recessive pattern of inheritance and present in infancy with muscle hypotrophy, weakness, respiratory insufficiency, short stature, and a marked reduction in RYR1 protein expression in muscle. Despite their severity, high prevalence and association with significant disability and early mortality, there are no treatments or disease-modifying therapies for RYR1-RM. A major barrier to therapy development has been the lack of an animal model that mirrors the early onset and clinical severity of recessive RYR1-RM. To overcome this barrier, we developed two mouse models of recessive RYR1-RM that pheno-copy key characteristics of the human disorder including myofiber hypotrophy, reduced muscle/body mass, muscle weakness, markedly reduced RYR1 expression, and premature death. The scientific premise of this proposal is that these new mouse models of RYR1-RM provide a unique opportunity to explore the underlying patho-mechanisms of RYR1-RM and test the therapeutic efficacy of mechanism-based interventions. The overall goal of the project is to elucidate the patho-mechanisms responsible for muscle dysfunction in recessive RYR1-RM and to develop and validate effective treatments. We hypothesize that reduced folding/stability of mutated RYR1 homotetramers results in increased RYR1 protein degradation that markedly reduces RYR1 expression, and that even a modest increase in either RYR1 expression or function will ameliorate the myopathy and prolong survival. Furthermore, we also hypothesize that reduced myofiber size in RYR1-RM is a key aspect of disease pathogenesis, that hypotrophy is due to epigenetic abnormalities, and that drugs that target the epigenome or promote muscle growth can ameliorate the disease phenotype. The validity of these hypotheses will rigorously evaluated in three specific aims. Aim 1 will characterize RYR1 expression, function and myopathy in two mouse models of severe, recessive RYR1-RM and assess the therapeutic potential of systemic treatment with ebselen, an FDA-approved drug and known RYR1 activator. Aim 2 will elucidate the mechanism(s) for reduced RYR1 expression in our mouse models of RYR1-RM mice and evaluate the therapeutic efficacy of systemic treatment with a chemical chaperone and ER stress inhibitor (4PBA). Aim 3 will determine the mechanisms leading to muscle hypotrophy in RYR1-RM mice and test the potential of treatment with either HDAC inhibitors or modulators of myofiber size. The results of these studies will provide novel insights into the patho-mechanisms responsible for reduced RYR1 expression and muscle fiber hypotrophy in recessive RYR1-RM and determine the therapeutic potential of several mechanism-based interventions designed to enhance RYR1 function, reduce RYR1 degradation, and limit muscle hypotrophy in pre-clinical models of recessive RYR1-RM.
编码骨骼肌I型兰诺定受体(RYR1)的基因突变导致广泛的 这些肌肉疾病共同构成了非营养不良肌病最常见的原因。最多的 重症RYR1相关性肌病(RYR1-RM)表现为隐性遗传和遗传 婴儿期,伴有肌肉萎缩、虚弱、呼吸功能不全、身材矮小和 RyR1蛋白在肌肉中的表达。尽管其严重性、高患病率以及与显著的 在残疾和早期死亡率方面,目前还没有针对RYR1-RM的治疗或疾病修正疗法。一位少校 治疗发展的障碍是缺乏反映早期发病和临床的动物模型 隐性RYR1-Rm的严重程度。为了克服这一障碍,我们开发了两种隐性遗传的小鼠模型。 RyR1-Rm是人类疾病的主要特征,包括肌纤维减少 肌肉/身体质量、肌肉无力、RYR1表达显著减少,以及过早死亡。 这项提议的科学前提是,这些新的RYR1-RM小鼠模型提供了一种独特的 有机会探索RYR1-RM的潜在致病机制并测试其治疗效果 以机制为基础的干预。该项目的总体目标是阐明致病机制。 负责隐性RYR1-RM的肌肉功能障碍,并开发和验证有效的治疗方法。 我们假设突变的RYR1同源异构体的折叠/稳定性降低会导致RYR1增加 蛋白质降解显著降低RYR1的表达,即使RYR1或RYR1的表达略有增加 表达或功能可改善肌病,延长生存期。此外,我们还假设 RYR1-RM中的肌纤维尺寸减小是疾病发病机制的一个关键方面,营养不良是由于 表观遗传学异常,靶向表观基因组或促进肌肉生长的药物可以改善 疾病表型。这些假设的有效性将从三个具体目标进行严格评估。 目的1将表征RYR1在两种严重隐性遗传性小鼠模型中的表达、功能和肌病 并评估FDA批准的药物Ebselen全身治疗的潜力 和已知的RYR1激活剂。目的2将阐明我们的小鼠RYR1表达降低的机制(S) RYR1-RM小鼠模型的建立及全身化学治疗的疗效评价 伴侣和内质网应激抑制物(4PBA)。目标3将确定导致肌肉萎缩的机制 并测试HDAC抑制剂或肌纤维调节剂的治疗潜力 尺码。这些研究的结果将提供对致病机制的新见解。 隐性RYR1-RM的RYR1表达降低和肌纤维萎缩及其治疗 旨在增强RYR1功能、降低RYR1的几种基于机制的干预措施的潜力 隐性RYR1-RM临床前模型中的降解和限制肌肉萎缩。

项目成果

期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Characterization of a novel zebrafish model of SPEG-related centronuclear myopathy.
  • DOI:
    10.1242/dmm.049437
  • 发表时间:
    2022-05-01
  • 期刊:
  • 影响因子:
    4.3
  • 作者:
    Espinosa, Karla G.;Geissah, Salma;Groom, Linda;Volpatti, Jonathan;Scott, Ian C.;Dirksen, Robert T.;Zhao, Mo;Dowling, James J.
  • 通讯作者:
    Dowling, James J.
Function of a mutant ryanodine receptor (T4709M) linked to congenital myopathy.
  • DOI:
    10.1038/s41598-023-41801-2
  • 发表时间:
    2023-09-05
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
  • 通讯作者:
Standardization of zebrafish drug testing parameters for muscle diseases.
Variants in ASPH cause exertional heat illness and are associated with malignant hyperthermia susceptibility.
  • DOI:
    10.1038/s41467-022-31088-8
  • 发表时间:
    2022-06-13
  • 期刊:
  • 影响因子:
    16.6
  • 作者:
  • 通讯作者:
Iron Dysregulation in Mitochondrial Dysfunction and Alzheimer's Disease.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES J DOWLING其他文献

JAMES J DOWLING的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES J DOWLING', 18)}}的其他基金

AAV mediated gene knockdown of PIK3C2B as a therapeutic strategy for X-linked myotubular myopathy and fatty liver disease
AAV 介导的 PIK3C2B 基因敲低作为 X 连锁肌管肌病和脂肪肝的治疗策略
  • 批准号:
    10753786
  • 财政年份:
    2023
  • 资助金额:
    $ 40.35万
  • 项目类别:
Environmental and Epigenetic Modifiers of Susceptibility to Malignant Hyperthermia and Environmental Heat Stroke
恶性高热和环境中暑易感性的环境和表观遗传因素
  • 批准号:
    10606166
  • 财政年份:
    2022
  • 资助金额:
    $ 40.35万
  • 项目类别:
Pathophysiology and Treatment of Recessive RYR1 Related Myopathy
隐性 RYR1 相关肌病的病理生理学和治疗
  • 批准号:
    10405495
  • 财政年份:
    2020
  • 资助金额:
    $ 40.35万
  • 项目类别:
Pathophysiology and Treatment of Recessive RYR1 Related Myopathy
隐性 RYR1 相关肌病的病理生理学和治疗
  • 批准号:
    10224943
  • 财政年份:
    2020
  • 资助金额:
    $ 40.35万
  • 项目类别:
Novel gene based therapy for nemaline myopathy
线状肌病的新型基因疗法
  • 批准号:
    10216977
  • 财政年份:
    2019
  • 资助金额:
    $ 40.35万
  • 项目类别:
Novel gene based therapy for nemaline myopathy
线状肌病的新型基因疗法
  • 批准号:
    10458505
  • 财政年份:
    2019
  • 资助金额:
    $ 40.35万
  • 项目类别:
Novel gene based therapy for nemaline myopathy
线状肌病的新型基因疗法
  • 批准号:
    10020762
  • 财政年份:
    2019
  • 资助金额:
    $ 40.35万
  • 项目类别:
Novel gene based therapy for nemaline myopathy
线状肌病的新型基因疗法
  • 批准号:
    10665673
  • 财政年份:
    2019
  • 资助金额:
    $ 40.35万
  • 项目类别:
CCDC78 and the Pathogenesis of Centronuclear Myopathy
CCDC78 与中心核肌病的发病机制
  • 批准号:
    8768983
  • 财政年份:
    2012
  • 资助金额:
    $ 40.35万
  • 项目类别:
CCDC78 and the pathogenesis of centronuclear myopathy
CCDC78与中心核肌病的发病机制
  • 批准号:
    8288935
  • 财政年份:
    2012
  • 资助金额:
    $ 40.35万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 40.35万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 40.35万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 40.35万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 40.35万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 40.35万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 40.35万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 40.35万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 40.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 40.35万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 40.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了